John Otrompke

8957 EDMONSTON RD

SUITE J

Articles

A new look at lipolysis

October 01, 2004

Boston - Improvements on a non-invasive alternative to liposuction may revolutionize medical procedures in this area, according to a presentation at this year's International Master Course on Aging Skin.

Laser mix-and-match

October 01, 2004

Boston - A presentation at this year's International Master Course on Aging Skin here suggests that some newer-generation laser models may be used in conjunction with others to treat previously difficult-to-reach violaceous vascular lesions, and even achieve greater results in non-ablative skin rejuvenation.

Gender Differences Noted

November 01, 2003

Chicago -- Two Singapore studies refuted the long-standing notion that Asian women have lower skin barrier function than other ethnic groups, according to findings presented at this year's L'Oreal Ethnic Skin and Hair Conference here in September.

Cultural Differences

November 01, 2003

Chicago - The dermatological ecology of South Africa, a context considerably different from its North American counterpart, was discussed at this year's L'Oreal Ethnic Skin and Hair Conference here from Sept. 19 to 21, 2003.

Lasers Offer More Options

November 01, 2003

Chicago - A pioneering researcher in the area of acne keloidalis nuchae recommended the use of Nd:YAG lasers set in non-ablative resurfacing mode and low fluence vascular lasers for treatment of the condition in African-Americans at this year's L'Oreal Ethnic Skin and Hair Conference here, Sept. 19-21. "We have utilized both lasers with success," says Fran E. Cook-Bolden, M.D.

When There's No Time for HAART to Start ...

August 01, 2003

Chicago - In the early days before protease inhibitors, Kaposi's sarcoma was considered a severe and dangerous ancillary condition that often was fatal to patients.

Bevacizumab Results Favorable But Not Definitive

August 01, 2003

Chicago - A phase II trial of a new recombinant agent in the fight against melanoma has accrued 28 patients so far, yielding interesting data but so far no conclusive results, according to an abstract presented at this year's annual meeting of the American Society of Clinical Oncology.

Verifying the Vaccine

August 01, 2003

Chicago - As patient accrual to phase III trials of Canvaxin therapeutic polyvalent cancer vaccine nears the 1,000-mark, a randomized phase II trial of the vaccine was reported at the annual meeting of the American Society of Clinical Oncology. The trial used an immunostimulant to enhance the antibody response to a tumor-associated antigen (TA90) found on melanoma cells.

Triple Peptide Vaccine

August 01, 2003

Chicago - Data involving the first 60 patients in a phase II clinical trial of a multi-epitope peptide vaccination, as combined with other agents, showed a median survival of 21 months for immunological responders as compared to 13 months in immunologic nonresponders.